Aidoc, a global leader in clinical AI, has raised $150 million in Series E funding to accelerate expansion of its clinical foundation model and enterprise AI platform, bringing total funding to over $500 million, less than a year after a growth round led by General Catalyst and Square Peg. The round was led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Investment Advisors, and NVentures, NVIDIA’s venture capital arm.
The New York-based company’s CARE foundation model received a landmark first FDA clearance earlier this year for a comprehensive foundation model-based triage system in clinical imaging. Aidoc currently analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals. The raise comes amid growing urgency around diagnostic errors and delays, which contribute to at least 400,000 deaths each year in the United States, driven by rising imaging volumes, workforce shortages, and growing clinical complexity.
The new capital will support further development of the CARE foundation model, expansion into additional clinical indications, and new capabilities including automated imaging draft report creation. It will also drive broader global deployment of the company’s aiOS enterprise AI platform as hospitals consolidate standalone tools under centralized AI governance frameworks.
KEY QUOTES:
By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error. We feel a deep responsibility to deploy CARE safely and at scale across health systems. This funding accelerates comprehensive disease coverage and advances end-to-end AI across CT and X-ray, spanning the full workflow, including pixel to draft report within two years.
Elad Walach, Co-Founder and CEO, Aidoc
Aidoc pairs advanced technology with regulatory rigor in a way that few companies have achieved. Health systems consistently describe tangible results, including improved radiology efficiency, shorter lengths of stay, and measurable financial returns. We believe this combination of innovation, safety, technical rigor, and operational discipline positions Aidoc as a long-term leader in clinical AI.
Christian Resch, Partner, Growth Equity at Goldman Sachs Alternatives
